# SNDL Inc.: overview SNDL · Nasdaq · CIK 1766600 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sndl.md) · [Financials](/companies/sndl/financials.md) · [Filings](/companies/sndl/filings.md) · [Insiders](/companies/sndl/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [56.1](/filings/0000950170-24-034351.md) | [712](/filings/0000950170-24-034394.md) | [909](/filings/0000950170-25-040545.md) | [920](/filings/0001193125-26-102524.md) | [946](/filings/0001193125-26-102524.md) | | Gross margin | % | [(16.0%)](/filings/0000950170-24-034351.md) | [19.7%](/filings/0000950170-24-034394.md) | [20.9%](/filings/0000950170-25-040545.md) | [26.1%](/filings/0001193125-26-102524.md) | [27.3%](/filings/0001193125-26-102524.md) | | Operating margin | % | [(239.4%)](/filings/0000950170-24-034351.md) | [(48.8%)](/filings/0000950170-24-034394.md) | [(18.0%)](/filings/0000950170-25-040545.md) | [(11.3%)](/filings/0001193125-26-102524.md) | [(0.7%)](/filings/0001193125-26-102524.md) | | Net margin | % | [(404.4%)](/filings/0000950170-24-034351.md) | [(47.1%)](/filings/0000950170-24-034394.md) | [(19.0%)](/filings/0000950170-25-040545.md) | [(10.3%)](/filings/0001193125-26-102524.md) | [(1.7%)](/filings/0001193125-26-102524.md) | | Diluted EPS | $ per share | not reported | [(1.46)](/filings/0000950170-24-034394.md) | [(0.67)](/filings/0000950170-25-040545.md) | [(0.36)](/filings/0001193125-26-102524.md) | [(0.06)](/filings/0001193125-26-102524.md) | | Free cash flow | $m | [(160)](/filings/0000950170-24-034351.md) | [(17.4)](/filings/0000950170-24-034394.md) | [(24.5)](/filings/0000950170-25-040545.md) | [46.3](/filings/0001193125-26-102524.md) | [58.1](/filings/0001193125-26-102524.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sndl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $13.8m | 10,214,013 | | Reduced −1,197,108 | | [CANNELL CAPITAL LLC](/funds/1058854.md) | 2026-06-30 | $11.7m | 8,639,381 | | Reduced −121,774 | | [Tidal Investments LLC](/funds/1600064.md) | 2026-06-30 | $7.2m | 5,334,370 | | Reduced −176,305 | | [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $3.2m | 2,357,401 | | Reduced −639,022 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.9m | 2,165,081 | | Added +286,969 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $2.9m | 2,116,500 | Put | Added +27,200 | | [MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.](/funds/1705339.md) | 2026-06-30 | $2.9m | 2,113,976 | | Reduced −125,388 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $2.7m | 1,970,467 | | Added +788,392 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $2.6m | 1,913,418 | | Added +351,097 | | [Ewing Morris & Co. Investment Partners Ltd.](/funds/1846838.md) | 2026-06-30 | $2.0m | 1,481,222 | | Added +180,000 | ## Recent filings [All 403 filings](/companies/sndl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 07:00 ET | [6-K](/filings/0001171843-26-006837.md) | Report of a foreign private issuer, period 2026-10-27 | 0001171843-26-006837 | | 2026-10-27 | 19:19 ET | [6-K](/filings/0001193125-26-432303.md) | Report of a foreign private issuer, period 2026-10-26 | 0001193125-26-432303 | | 2026-10-15 | 17:00 ET | [6-K](/filings/0001171843-26-006673.md) | Report of a foreign private issuer, period 2026-10-15 | 0001171843-26-006673 | | 2026-10-14 | 16:30 ET | [6-K](/filings/0001171843-26-006626.md) | Report of a foreign private issuer, period 2026-10-14 | 0001171843-26-006626 | | 2026-10-06 | 07:00 ET | [6-K](/filings/0001171843-26-006436.md) | Report of a foreign private issuer, period 2026-10-06 | 0001171843-26-006436 | | 2026-09-08 | 14:37 ET | [6-K](/filings/0001193125-26-385027.md) | Report of a foreign private issuer, period 2026-09-08 | 0001193125-26-385027 | | 2026-08-04 | 16:35 ET | [6-K](/filings/0001171843-26-005205.md) | Report of a foreign private issuer, period 2026-08-04 | 0001171843-26-005205 | | 2026-07-28 | 07:00 ET | [6-K](/filings/0001171843-26-004910.md) | Report of a foreign private issuer, period 2026-07-28 | 0001171843-26-004910 | | 2026-07-28 | 18:04 ET | [6-K](/filings/0001193125-26-318366.md) | Report of a foreign private issuer, period 2026-07-27 | 0001193125-26-318366 | | 2026-07-27 | 11:58 ET | [6-K](/filings/0001171843-26-004890.md) | Report of a foreign private issuer, period 2026-07-27 | 0001171843-26-004890 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-102524.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1766600 - Tickers: SNDL - Exchange: Nasdaq - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: A0 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:05 ET. No prices; not investment advice.